[Skip to Navigation]
Editorial
September 2018

Improving Evaluation of Patients With Cognitive Impairment With Amyloid Positron Emission Tomography

Author Affiliations
  • 1Department of Neurology, Alpert Medical School of Brown University, Providence, Rhode Island
  • 2Department of Psychiatry, Alpert Medical School of Brown University, Providence, Rhode Island
  • 3Butler Hospital, Providence, Rhode Island
JAMA Neurol. 2018;75(9):1045-1046. doi:10.1001/jamaneurol.2018.1010

Approximately 20% to 30% of patients diagnosed as having Alzheimer disease (AD) in an expert setting do not meet pathological criteria at autopsy.1,2 In 2 recent clinical trials, 20% of all patients (and more than 33% of those who were noncarriers of the apolipoprotein E ε4 allele) with mild or moderate Alzheimer dementia did not show an elevation in amyloid on positron emission tomography (PET) imaging.3,4 Individuals with a nonamyloid amnestic dementia in those 2 trials had a more benign clinical course.

Add or change institution
×